Serum testosterone levels decline gradually and progressively with aging in men. Many manifestations associated with aging in men, including muscle atrophy and weakness, osteoporosis, reduced sexual functioning, and increased fat mass, are similar to changes associated with testosterone deficiency in young men. These similarities suggest that testosterone supplementation may prevent or reverse the effects of aging. A MEDLINE search was performed to identify studies of testosterone supplementation therapy in older men. A structured, qualitative review was performed of placebo-controlled trials that included men aged 60 and older and evaluated one or more physical, cognitive, affective, functional, or quality-of-life outcomes. Studies focusing on patients with severe systemic diseases and hormone deficiencies related to specific diseases were excluded.
Serum testosterone levels decline gradually and progressively with aging in men. Many manifestations associated with aging in men, including muscle atrophy and weakness, osteoporosis, reduced sexual functioning, and increased fat mass, are similar to changes associated with testosterone deficiency in young men. These similarities suggest that testosterone supplementation may prevent or reverse the effects of aging. A MEDLINE search was performed to identify studies of testosterone supplementation therapy in older men. A structured, qualitative review was performed of placebo-controlled trials that included men aged 60 and older and evaluated one or more physical, cognitive, affective, functional, or quality-of-life outcomes. Studies focusing on patients with severe systemic diseases and hormone deficiencies related to specific diseases were excluded.
In healthy older men with low-normal to mildly decreased testosterone levels, testosterone supplementation increased lean body mass and decreased fat mass. Upper and lower body strength, functional performance, sexual functioning, and mood were improved or unchanged with testosterone replacement. Variable effects on cognitive function were reported, with improvements in some cognitive domains (e.g., spatial, working, and verbal memory). Testosterone supplementation improved exercise-induced coronary ischemia in men with coronary heart disease, whereas angina pectoris was improved or unchanged. In a few studies, men with low testosterone levels were more likely to experience improvements in lumbar bone mineral density, self-perceived functional status, libido, erectile function, and exercise-induced coronary ischemia with testosterone replacement than men with less marked testosterone deficiency. No major unfavorable effects on lipids were reported, but hematocrit and prostate specific antigen levels often increased.
Based on these results, testosterone supplementation cannot be recommended at this time for older men with normal or low-normal testosterone levels and no clinical manifestations of hypogonadism. However, testosterone replacement may be warranted in older men with markedly decreased testosterone levels, regardless of symptoms, and in men with mildly decreased testosterone levels and symptoms or signs suggesting hypogonadism. The longterm safety and efficacy of testosterone supplementation remain uncertain. Establishment of evidence-based indications will depend on further demonstrations of favorable clinical outcomes and symptomatic, functional, and quality-of-life benefits in carefully performed, long-term, randomized, placebo-controlled clinical trials. J Am Geriatr Soc 51:101-115, 2003. Key words: testosterone; aging; hormone replacement therapy; androgens; hypogonadism n cross-sectional and longitudinal studies, aging in men is associated with a gradual and progressive decline in serum total testosterone concentrations as a result of primary testicular and secondary hypothalamic-pituitary dysfunction. [1] [2] [3] [4] [5] [6] [7] [8] A substantial proportion of older men (ranging from 20% of 60-year-old to 50% of 80-year-old men) exhibit serum total testosterone levels below the normal range for younger men. 8 Because concentrations of sex hormone-binding globulin (SHBG), the main circulating binding protein for testosterone, increase with age, the age-related decline in serum free or bioavailable (non-SHBG-bound) testosterone is greater than that of total testosterone, and a larger proportion of older men have levels of free or bioavailable testosterone below the normal range for younger men. When low total testosterone levels occur in healthy older men, the level is usually mildly decreased (e.g., 2.5-3.0 ng/mL) and associated with symptoms such as erectile dysfunction, loss of libido, and muscle weakness. In frail older men in rehabilitation units or living in nursing homes, low testosterone levels are more prevalent than in community-dwelling men of the same age, 9, 10 and average free testosterone levels are usually below the normal range for healthy young men. 10, 11 Testosterone levels are often low in a number of chronic medical illnesses (e.g., renal failure, malignancy) and with the use of certain medications (e.g., glucocorticoids, opiates) in older men. Furthermore, clinical findings suggesting hypogonadism are extremely common in these men.
In hypogonadal young men, the manifestations of androgen deficiency are fully or partially reversible with testosterone replacement, including decreased libido and energy, inability to concentrate, erectile dysfunction, weakness, and decreased muscle and bone mass. Because apparently healthy men often experience similar changes in association with reductions in serum testosterone levels with aging, testosterone supplementation has been proposed as a potential approach to prevent or reverse these conditions. For example, aging is associated with alterations in body composition, including decreased muscle mass and strength, increased fat mass, and decreased bone mineral density (BMD). These alterations in body composition contribute to overall frailty and an increased risk of falls and fractures. The anabolic effects of testosterone are well known. In young men, testosterone supplementation increases lean body mass and strength not only in men with hypogonadism, but also in men with normal testosterone levels receiving supraphysiological doses of testosterone. 12 Moreover, uncontrolled studies have demonstrated an increase in BMD with testosterone treatment in hypogonadal men [13] [14] [15] and eugonadal middle-aged and older men with idiopathic osteoporosis. 16 Low testosterone concentrations are associated with an increased risk of low-trauma hip fracture. [17] [18] [19] However, the goal of therapy in older men is not only to improve age-related changes in body composition, but also to effect meaningful changes in strength, fall and fracture risk, and functional status.
Disorders of mood, sexual functioning, and cognition are common in older and hypogonadal young men, but the effects of testosterone on these conditions have not been evaluated extensively in older men. In hypogonadal young men, testosterone is required for the maintenance of normal libido and sexual functioning. 20 Androgen levels are positively correlated with spatial ability in hypogonadal young men, 21 and improvement in sexual function, mood, perceived well-being, and ability to concentrate have been reported with testosterone supplementation. [22] [23] [24] [25] [26] [27] [28] In older men, lower testosterone levels are associated with depressed mood and reduced cognitive function. [29] [30] [31] The role of testosterone in the development of coronary heart disease (CHD) in men is controversial. Men have a higher incidence of CHD than women of similar age, and it has been suggested that testosterone may predispose to the development of CHD. However, in men referred for coronary angiography, low testosterone levels were associated with an increased risk of coronary atherosclerosis. 32 In fact, most epidemiological studies suggest a favorable or neutral rather than an adverse effect of testosterone on CHD in men. 33 Furthermore, testosterone was found to induce relaxation of coronary arteries and increase coronary blood flow in animal models. 34, 35 Nevertheless, the clinical significance of these observations is unclear.
Several important trials of testosterone supplementation in older men have been published over the past few years. As a result, there is now more and better information on which to base an assessment of its potential benefit. A number of reviews of testosterone replacement therapy have been published recently (e.g., 1, [36] [37] [38] 88, 89, 90 ), but, because none of these reviews used a systematic approach to the literature review and study selection process, they may be subject to bias in their conclusions. To the authors' knowledge, this is the first review of testosterone replacement therapy in older men to describe a structured methodology, including a comprehensive literature search strategy and predefined study selection criteria. Given the potential for a strong placebo effect for many endpoints in studies of hormone supplementation, it seemed appropriate to limit the review to evidence from placebo-controlled trials. To assess the full spectrum of potential clinical applications of testosterone, an inclusive approach was taken rather than limiting the review to specific outcome measures such as body composition measurements. Accordingly, a qualitative review was performed. Both authors and a trained research assistant independently assessed study design and quality of the methods used in each trial. Trial methodology was assessed according to the method of Jadad et al., 39 using a quality scale to assess randomization, double blinding, and description of withdrawals and dropouts. One point was given for each of the following: (1) the study was described as randomized, (2) the study was described as double-blind, and (3) there was a description of withdrawals and dropouts. An additional point was given for each of the following: (1) the method of randomization was described and was appropriate and (2) the method of double blinding was described and was appropriate. A point was deducted for each of the following: (1) the method of randomization was described and was inappropriate and (2) the method of double blinding was described and was inappropriate. (Criteria for determining appropriateness were as defined by Jadad et al. 39 ) The quality score of abstracts was based only on information provided in the abstract and may therefore have underestimated (or overestimated) actual study quality. Disagreements regarding inclusion of articles and quality scores were resolved by discussion.
METHODS
Placebo-controlled trials were included if they involved participants who were male and aged 60 and older and the treatment intervention was a preparation of testosterone. However, to ensure that the review remained focused on older people, trials involving study populations with a mean age of less than 50 were excluded. As a result, several studies that involved subjects aged 60 and older but also had a high proportion of young adult subjects were excluded from consideration (e.g., 25, 27, 28, 40, 41 ). Peerreviewed studies and trials published in abstract form with a quality score less than two were excluded. In addition, because of the decreased opportunity for peer review and the relative lack of methodological detail, trials published as letters or abstracts were included only if the study was clearly identified as a double-blind, placebo-controlled study. For studies published in peer-reviewed journals, trials clearly identified as nonrandomized and trials without a placebo control group were excluded from consideration, although studies with a crossover design and studies without a statement of randomization were allowed and noted as such in the tables. Studies whose purpose was dose finding rather than treatment were excluded. Moreover, trials intended primarily to study subjects with severe or unstable systemic illnesses such as burns, advanced cancer, and human immunodeficiency virus infection or subjects with hormone deficiencies due to specific diseases (e.g., Klinefelter's syndrome) rather than "normal" human aging were excluded. Finally, the authors received no financial support other than Veterans Affairs medical research funds for any portion of the data collection, analysis, or interpretation, nor did a funding organization exert any control over the approval of this manuscript for publication.
RESULTS
Twenty-nine studies met the criteria for inclusion and exclusion, four of which were published only in abstract form, with sample sizes ranging from six to 108 and study durations ranging from single-dose administration to 3 years (Table 1) . Mean baseline circulating testosterone levels in subjects participating in these studies ranged from normal to moderately below the lower end of the normal range for young adult men and typically increased into the middle of the normal young adult range with supplementation. Many studies, including all trials of more than 3 months of supplementation save one, 61 required study subjects to have baseline testosterone levels below a specified value (e.g., 1 standard deviation below the mean for young men) or below the reference range for young adult men. [42] [43] [44] [45] [46] [47] [48] [49] [50] [52] [53] [54] 58, 62, 67, 69, 70, 76, 77 The remaining trials enrolled subjects with a wide range of baseline levels, but only a few studies enrolled subjects with mean total testosterone levels well below the reference range for young men. 58, 68, 70, 75 Moreover, only one study stratified its subjects by baseline testosterone level before random treatment group allocation. 44, 53 Body Composition All but three trials 51, 56, 57 evaluating body composition and muscle strength limited enrollment to subjects with baseline testosterone levels below a specified value. In general, lean body mass increased and fat mass decreased with testosterone administration, [42] [43] [44] [45] [46] [47] [48] [49] [50] although these changes were not significant in all cases 42, 45, 51 (Table 2) . These effects on body composition were more consistently observed in studies with a long duration of testosterone supplementation 42, [44] [45] [46] [47] 49, 50, 54 than in studies of 3 months' duration or less. 43, 51, 52 However, relatively few studies of shorter duration evaluated parameters of body composition. Visceral fat mass decreased in men with abdominal obesity. 45 Despite these effects, body circumference measurements in testosterone-treated subjects were unchanged compared with placebo or from pretreatment baseline. 42, 43, 46, 52 Bone Mineral Density Testosterone supplementation for 1 year prevented bone loss at the femoral neck 49 and increased BMD of the lumbar spine 50 in older men with total testosterone levels below the normal range for younger men. In another study, BMD increased in both placebo-and testosterone-treated subjects over a 3-year period, but the increase was not significantly greater in subjects treated with testosterone. 53 However, linear regression analysis of those data suggested that testosterone supplementation did increase lumbar spine bone density in men with the lowest baseline testosterone levels. A 6% increase in bone density would be expected in men with testosterone levels of 2.0 ng/mL, whereas bone density would not change in men with testosterone levels of 4.0 ng/mL. 53 Biochemical indices of bone turnover decreased in a shorter-term (3-month) study, 43 but bone turnover was unchanged in 1-year 49 and 3-year 53 studies.
Muscle Strength and Functional Ability
In healthy older men receiving testosterone, hand-grip strength increased 42, 56 or was unchanged, 43,44,52 whereas knee extension and flexion strength was unaffected. 44, [49] [50] [51] [52] Hand-grip strength increased in studies involving both short 56 and relatively long 42 durations of testosterone supplementation, although testosterone treatment for 3 years did not affect hand-grip strength in another study. 44 Testosterone administration for 3 years did not improve timed walking or timed stair climbing. 44 However, in a preliminary study, timed walking and stair climbing improved in older men treated with testosterone for 1 month. 51 Self-assessment of physical functioning did not change over 3 years of testosterone treatment, but a decline was observed in placebo-treated men, becoming significantly worse than in treated subjects by the end of the study. 44 Using regression analysis of these data, the greatest effect of testosterone on perception of physical functioning occurred in subjects with the lowest baseline testosterone levels. Aerobic capacity was not significantly improved after 6 months of testosterone supplementation, although a positive effect of combined testosterone and growth hormone administration on aerobic capacity was greater than with growth hormone alone. 54 In men undergoing total knee or hip arthroplasty, administration of supraphysiological testosterone doses for 4 weeks preoperatively did not significantly affect postoperative functional status, but there was a trend toward improvement in some measures of functional independence in men receiving testosterone treatment. 55 Only one trial evaluated the effects of testosterone supplementation on function and strength in frail, debilitated older men. In subjects undergoing rehabilitation on an inpatient geriatric evaluation and management (GEM) unit, grip strength and functional status improved with testosterone administration, 56 but length of stay on the inpatient unit was unaffected.
A preliminary study found that 3 weeks of supraphys-iological testosterone supplementation increased growth hormone secretion in older but not in young men, whereas low-dose testosterone supplementation did not increase growth hormone in either group 57 (Table 2) .
Sexual Function and Mood
Testosterone's effects on sexual functioning and mood were variable and not clearly related to duration of treatment (Table 3 ). Testosterone treatment improved or tended to improve libido in studies in which it was assessed. 43, 58, [60] [61] [62] Testosterone improved erectile function in some 58 but not all 59,60 studies of older men with preexisting erectile dysfunction. In the study that showed a beneficial effect of testosterone on erectile dysfunction, mean baseline testosterone levels were significantly below the normal reference range. 58 By comparison, mean testosterone levels were higher in the two studies that found no effect on erectile function, 59 ,60 but reference ranges were not provided in either study. Some healthy older men reported increased feelings of well-being, energy, 43, 45, 61 and frequency of sexual activity 60,62 during treatment, but energy, 44 mood 42, 59, 60, 63, 64 and sexual functioning 44, 50 were unchanged in other studies of healthy men treated for up to 3 years. Scores on the Geriatric Depression Scale improved in frail, debilitated older men. 56 
Cognitive Function
Testosterone's effects on cognitive function were mixed. Some studies involving physiological 63 to mildly supraphysiological 64, 65 supplementation reported improvement in spatial cognition, 63, 65 spatial and verbal memory, 65 and working memory (the ability to hold and manipulate information in short-term memory before responding), 64 but other investigators found no effect of testosterone treatment on memory, recall, or verbal fluency. 42 In addition, in contrast to placebo-treated subjects, verbal fluency failed to improve with practice in subjects treated with mildly supraphysiological doses of testosterone, 66 suggesting that testosterone supplementation may adversely affect some cognitive functions in older men. Only one study assessing cognitive endpoints involved more than 3 months of testosterone treatment, 42 therefore differences between short-term and long-term effects of testosterone on cognition could not be assessed.
Lipids and Cholesterol
Regardless of the baseline testosterone level and duration of testosterone therapy, total and low density lipoprotein (LDL) cholesterol levels were reduced 43, 45, 67, 68 or unchanged, 42, 52, 87 whereas high density lipoprotein (HDL) cholesterol levels were unchanged. 42, 43, 45, 67, 68, 87 Testosterone inhibited triglyceride uptake and lipoprotein lipase activity in abdominal but not in femoral subcutaneous fat, suggesting that testosterone may regulate the proportion of fat deposited in central and peripheral locations.
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Coronary Heart Disease
In five studies of older men with established CHD, improvements in exercise-induced ST-segment depression on electrocardiography were observed after acute 70, 71 and chronic [72] [73] [74] testosterone administration and with physiological 72 and supraphysiological 70, 71, 73 doses (Table  4 ). The beneficial effects of testosterone on ST-segment depression were observed in men with low-normal 71, 72 and more markedly decreased 70 baseline levels of testosterone. No effects on time to onset of angina pectoris during exercise testing or anginal frequency were reported in studies of a single dose or 12 weeks of testosterone, 70, 72 but angina pectoris decreased and exercise tolerance improved in other subjects receiving testosterone for 6 to 8 weeks. 74 In addition, subjects with angina pectoris who received testosterone for 3 months reported a significant improvement in all quality of life domains assessed by the SF-36 health survey questionnaire, especially pain perception and role limitation resulting from physical problems. 72 Finally, brachial artery caliber increased after acute testosterone infusion in men with CHD, suggesting that the effects of testosterone on the heart may be due to a vasodilatory effect on the coronary arteries. 75 None of these studies were of sufficient size or duration to allow an assessment of the effects of testosterone on overall cardiovascular morbidity and mortality.
Prostate Gland
In studies reporting effects of testosterone on the prostate, none reported an increase in voiding symptoms, prostate examination abnormalities, or postvoid residual urine volumes during treatment, 42, 43, 45, 49, 50, 53, 55, 61, 76 but prostate size increased 12% in one study. 61 Although five studies reported no effect of testosterone therapy on prostate specific antigen (PSA) levels, 45, 50, 61, 72, 76 the PSA increased slightly but significantly in four others 43, 49, 53, 65 after as little as 6 weeks of treatment. 65 This increase in PSA occurred irrespective of the baseline testosterone level. In studies reporting PSA levels, 42, 43, 49, 52, 53, 65 the average baseline PSA ranged from 1.0 to 2.4 ng/mL, with an increment of 0.6 to 1.0 ng/mL during treatment. However, PSA levels remained within the normal range, except for one subject whose PSA increased from 3.5 ng/mL at baseline to 4.1 ng/ mL during testosterone supplementation. 65 
Erythrocytosis
In most studies, the mean hematocrit increased during treatment from 2.5% to 5% over baseline values, and between 6% and 25% of study subjects developed hematocrit elevations above the normal range. 42, 43, 52, 53, 73, 76, 77 No significant change in the hematocrit was observed in some 49, 72 but not all 53 trials that used transdermal testosterone supplementation. 68 NA NA NA ↔ ↓ TC, LDL-C No acne, gynecomastia ↔ HDL-C *Supraphysiological supplementation. ↑ ϭ increased; ↓ ϭ decreased; ↔ ϭ unchanged; NA ϭ not assessed/not reported; PSA ϭ prostate specific antigen (ng/mL); DRE ϭ digital rectal examination; HCT ϭ hematocrit; HGB ϭ hemoglobin; BPH ϭ benign prostatic hyperplasia; PVR ϭ postvoid residual urine volume; NS ϭ not significant versus placebo group; TC ϭ total cholesterol; LDL-C ϭ low-density lipoprotein cholesterol; HDL-C ϭ high-density lipoprotein cholesterol; TG ϭ triglyceride.
Sleep Apnea
In the one study that formally assessed sleep apnea, sleep studies did not reveal a change in the occurrence of sleep apneas or hypopneas in men receiving testosterone treatment 53 
Effect of Quality Score and Baseline Testosterone
The effects of testosterone supplementation did not differ systematically for any endpoint based on whether studies had a higher or a lower quality score (data analysis not shown).
Finally, the effects of testosterone supplementation were compared between studies enrolling subjects with baseline testosterone levels below a specified value [42] [43] [44] [45] [46] [47] [48] [49] [50] [52] [53] [54] 58, 62, 67, 69, 70, 76, 77 and those with no upper limit on testosterone levels (Tables 2-5 ). It was hypothesized that studies enrolling only men with levels below a cutoff value would be more likely to show a favorable effect of testosterone supplementation than studies without this restriction. Erectile function improved in a study enrolling only older men with low baseline testosterone levels, 58 whereas two studies without this limitation did not find an improvement in erectile function with testosterone administration. 59, 60 One study limiting enrollment to men with low testosterone levels reported an improvement in subjective well-being in some subjects, 43 whereas only one 56 of five studies without this limitation reported an improvement in mood. No other systematic differences were observed based on whether study enrollment was limited to men with testosterone levels below a given level.
DISCUSSION
This review found evidence from placebo-controlled trials that testosterone supplementation increases lean body mass and decreases fat mass in healthy older men with low-normal or mildly decreased testosterone levels. Furthermore, lumbar spine bone density appeared to increase and bone loss at the femoral neck was prevented in men with circulating testosterone levels below normal values for young men. Testosterone's effects on strength and function were more mixed, but some studies found an increase in upper extremity strength and improved performance of some functional tasks. Self-perceived physical functioning, like bone density, was more likely to improve in subjects with the lowest baseline testosterone levels.
Sexual functioning, energy, mood, libido and subjective well-being were improved or unchanged with testosterone therapy. Testosterone therapy more consistently caused an activation in sexual behavior and libido than an improvement in erectile function. Testosterone improved aspects of spatial ability and spatial, working, and verbal memory in some studies. However, supraphysiological testosterone appeared to worsen cognition in another study by blocking the practice effect on verbal fluency. In fact, most of these effects on memory and verbal fluency were observed in subjects receiving mildly supraphysiological testosterone supplementation. By comparison, physiological supplementation improved spatial cognition but had no effect on other cognitive domains in one study, 63 whereas another reported no effect on memory and verbal fluency. 42 In contrast to the HDL-suppressive effects of testosterone replacement in severely hypogonadal younger men 78 or supraphysiological testosterone treatment, 79 in older men testosterone generally had little effect on HDL cholesterol, and total and LDL cholesterol levels were decreased or unchanged. In men with CHD, testosterone consistently improved electrocardiographic evidence of exercise-induced coronary ischemia, regardless of whether testosterone supplementation was physiological or supraphysiological, or whether baseline testosterone levels were low-normal or more markedly decreased. Effects on angina pectoris were more variable.
Testosterone therapy was generally well tolerated, although abnormal elevations in the hematocrit occurred in many subjects, especially those receiving high-dose parenteral testosterone. PSA levels often increased slightly but significantly, mostly within the normal range (Ͻ4 ng/mL).
Taken together, these findings suggest that testosterone replacement in mildly androgen-deficient older men may have potentially beneficial effects on body composition, muscle strength, sexual functioning, subjective wellbeing, and manifestations of CHD. In addition, there is evidence for short-term improvement in some functional measures of physical performance. However, it is unclear whether these effects will result in long-term improvements in clinical outcomes such as prevention of frailty, fractures, and coronary events, and it is unknown whether the long-term benefits outweigh the potential risks.
Only one study identified in this review demonstrated an improvement in quality of life outcomes with testosterone supplementation, 72 although others reported improvement in energy, mood, and other factors that may enhance quality of life. However, most studies of testosterone supplementation were insufficiently powered to demonstrate absence of efficacy of testosterone on mood and other quality of life-related endpoints. In addition, the "generic" instruments used in these studies to assess quality of life may not have been sensitive to change. The Androgen Deficiency in Aging Males questionnaire, a screening tool for symptoms of testosterone deficiency, includes questions that are condition specific and relevant to quality of life (e.g., decrease in libido and erections, lack of energy). 91 It represents a step toward the development of a qualityof-life assessment instrument that is specific for men with age-related androgen deficiency. It may be difficult to demonstrate improved function and quality of life in men who are healthy and living independently, as were most of the subjects enrolled in these studies. Testosterone supplementation may have a greater effect on functional status in frail, functionally dependent older men, based on the high prevalence of hypogonadism and catabolic states in this population. One small trial performed in a GEM unit milieu suggests that such patients may benefit functionally from testosterone replacement, 56 but the merits of testosterone therapy in debilitated older men remain largely unexplored.
It is unknown whether long-term testosterone supplementation in older men will lead to an increase in diseases such as clinically significant prostate cancer, benign prostatic hyperplasia, and cardiovascular disease. Given their high prevalence rates in older men, even a small unfavorable effect of testosterone on these conditions may outweigh the potential long-term benefits of treatment. The apparent absence of unfavorable effects on the lipid profile in these studies is noteworthy, but a significant undetected adverse lipid effect cannot be completely excluded because of the relatively small number of study subjects (n ϭ 328 in studies reporting lipid profiles) and the possibility of a beta error. Moreover, the increases in hematocrit and PSA levels in many subjects indicate that close monitoring is necessary in men receiving testosterone replacement. Erythrocytosis is less likely to develop when low-dose testosterone replacement regimens are used (e.g., patches or low-dose injections). These regimens minimize the stimulation of erythropoiesis associated with supraphysiological peak circulating testosterone levels, 1, 36, [88] [89] [90] although erythrocytosis may still occur in some men. 53 Studies in hypogonadal men have implicated testosterone replacement in the development or worsening of obstructive sleep apnea. 80 No differences in the occurrence of sleep apneas and hypopneas were reported in testosterone compared with placebotreated subjects over 3 years, 53 but a clinically important effect of testosterone on sleep apnea in some individuals is still possible. Therefore, symptoms suggesting sleep apnea (e.g., daytime somnolence, excessive snoring) should be monitored in men receiving testosterone.
There is increasing agreement among andrologists that testosterone replacement therapy is indicated in older men with total testosterone levels consistently below 2.0 ng/mL, regardless of whether symptoms are present. 81 Consistent with this view, some studies included in this review found that older men with low testosterone levels were more likely to experience improvements in lumbar BMD, self-perceived functional status, libido, erectile function, and exercise-induced coronary ischemia than men with less marked testosterone deficiency. 44, 53, 58, 59, 71, 72 Based on this evidence that the benefits of testosterone administration may be greatest in more severely androgendeficient older men, this review attempted to group studies for analysis by baseline testosterone levels. However, several problems were encountered in this analysis, and meaningful overall conclusions could not be made. First, only a few studies enrolled subjects with mean testosterone levels well below the normal range, 58, 68, 70, 75 whereas most studies included subjects with levels ranging from low-normal to mildly decreased. Second, only one trial stratified its subjects by baseline testosterone levels. 44, 53 Third, studies employed different methods of assessing baseline testosterone levels, including total, bioavailable, and free testosterone levels. Fourth, reference ranges were not included for comparison in a number of studies. Finally, when testosterone reference ranges were disclosed, there was significant variation between studies, reflecting differences in methodology.
Although it was impossible to analyze study results by baseline testosterone level, this review found that trials enrolling subjects with baseline testosterone levels below a specified value were more likely to report an improvement in erectile function and mood than studies with no upper limit on testosterone levels. However, these observations were based on data from a small number of subjects. Clearly, further studies are needed to determine the effects of testosterone supplementation in older men with markedly decreased testosterone levels. In addition, trials with sufficient numbers of subjects should stratify participants according to baseline testosterone level before randomization.
This review of testosterone replacement therapy in older adults has a number of inherent limitations. Its scope was intentionally broad, to assess the range of potential clinical applications of testosterone in older men. Broadbased narrative reviews may be the most appropriate method of describing current developments in fields where existing research is preliminary and there is a limited number of high-quality studies, 82, 83 but traditional narrative reviews may offer inappropriate clinical recommendations based on a biased sampling of the literature or "expert opinion" that is not evidence based. In an attempt to minimize bias and to provide evidence-based conclusions, a comprehensive literature search was performed, a priori criteria were specified for study selection, these criteria were rigorously applied, and the quality of the articles included in this review was assessed. In addition, symposium proceedings were searched for appropriate abstracts, to minimize potential publication bias in the event that studies showing a positive treatment effect were more likely to be published than "negative" studies. 84 Despite the broad scope of this review, some potential applications of testosterone in older men were not addressed. Studies primarily intended to evaluate hormone deficiencies due to specific diseases (e.g., Klinefelter's or Kallmann's syndromes) were excluded, thereby limiting the generalizability of the findings to older men in good health or with testosterone deficiency related to acute or chronic disease. In addition, the exclusion of trials that were not placebo controlled undoubtedly resulted in omission of a number of well-performed studies. Some of these studies may suggest other potential clinical applications or provide additional insight into the potential benefits and risks of testosterone replacement. However, on balance, this review was stronger and less subject to bias because of the structured approach to article selection. Finally, androgenic preparations other than testosterone may be reasonable alternatives to testosterone for supplementation in older men. For example, a recent randomized, placebo-controlled study of dihydrotestosterone gel treatment for 3 months in mildly androgen-deficient older men demonstrated decreased fat mass, decreased total and LDL cholesterol without a change in HDL cholesterol, and an increase in some measures of lower extremity strength without apparent adverse effects. 85 The relative merits of testosterone versus dihydrotestosterone supplementation in older men remain to be clarified.
It is possible that the inclusion of preliminary studies published only in abstract form could have biased the conclusions of this review. In addition, random group allocation could not be confirmed in four peer-reviewed studies and one abstract. 55, 58, 66, 68, 74 The likelihood of bias was minimized by requiring a minimum quality score of two for peer-reviewed studies and preliminary reports published in abstract form. 39, 86 Furthermore, quality scores for abstracts arguably would have been upgraded more often than downgraded if additional information on study methods had been available.
A detailed discussion of the clinical evaluation and management of low testosterone levels in older men is beyond the scope of this review, and the reader is referred to several recent reviews. 1, 36, 38, [88] [89] [90] Determining the long-term safety and efficacy of testosterone supplementation therapy will be a formidable challenge. By analogy to estrogen replacement therapy in postmenopausal women, a full assessment of the benefits and risks of testosterone replacement would require largescale, long-term, randomized, controlled trials to evaluate its effects on cardiovascular and prostate disease morbidity and mortality. Unfortunately, well-controlled trials of this magnitude are unlikely to be completed in the near future. In the interim, studies may identify subsets of older men most likely to benefit from testosterone supplementation. For example, such studies may provide further support for a reduction in fracture risk in older men with osteoporosis, for functional improvement in frail men living in nursing homes, and for a reduction in cardiovascular morbidity.
In conclusion, current data from placebo-controlled clinical trials do not support testosterone supplementation in healthy, asymptomatic older men with normal to low-normal testosterone levels outside of controlled clinical studies. However, this review found evidence for potentially beneficial effects of testosterone in men with decreased testosterone levels and symptoms and signs suggesting hypogonadism (e.g., decreased bone density, muscle mass, strength and libido; impaired sexual function; increased adiposity; and symptomatic CHD), especially if severe. Based on these findings, a trial of testosterone replacement therapy is reasonable in such men, if contraindications (e.g., prostate or breast cancer, polycythemia, or untreated sleep apnea) are absent. In addition, testosterone supplementation may be beneficial in older men with markedly decreased testosterone levels regardless of symptoms. To our knowledge, no randomized, controlled trials of testosterone replacement therapy extending more than 3 years have been performed in older men. Therefore, the long-term benefits and risks of testosterone treatment in older men remain unknown. Nevertheless, if additional well-controlled studies confirm important functional, symptomatic, or quality-oflife benefits of testosterone replacement, the potential long-term risks of supplementation may be acceptable for many older men.
